Affiliations 

  • 1 UKM Medical Molecular Biology Institute (UMBI), Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras Kuala Lumpur, Malaysia
  • 2 Department of Pediatrics, Hospital Putrajaya, Jalan P9, Federal Government Administration Centre, Precint 7, 62250 Putrajaya, Malaysia
  • 3 Department of Pediatrics, UKM Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras Kuala Lumpur, Malaysia
  • 4 UKM Medical Molecular Biology Institute (UMBI), Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras Kuala Lumpur, Malaysia. Electronic address: nor_azian@ppukm.ukm.edu.my
  • 5 Department of Pediatrics, UKM Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras Kuala Lumpur, Malaysia. Electronic address: bilkis@ppukm.ukm.edu.my
Clin Chim Acta, 2018 Sep;484:141-147.
PMID: 29807018 DOI: 10.1016/j.cca.2018.05.048

Abstract

BACKGROUND: Osteogenesis imperfecta (OI) is a rare genetic bone disease characterized by bone fragility and low bone mass. OI was mainly caused by genetic mutations in collagen genes, COL1A1 and COL1A2. Nevertheless, new genes have been identified to be causally linked to OI. The clinical features between each OI groups share great similarities and it is sometimes difficult for clinicians to diagnose the disease accurately. Here, we identify the genetic mutations of OI patients from Malaysia and correlate the genetic mutations with the clinical features.

METHOD: Targeted sequencing of fourteen genes panel was performed to identify the mutations in 29 OI patients with type I, III, IV and V disease. The mutations were determined using Ion Torrent Suite software version 5 and variant annotation was conducted using ANNOVAR. The identified mutations were confirmed using Sanger sequencing and in silico analysis was performed to evaluate the effects of the candidate mutations at protein level.

RESULTS: Majority of patients had mutations in collagen genes, 48% (n = 14) in COL1A1 and 14% (n = 4) in COL1A2. Type I OI was caused by quantitative mutations in COL1A1 whereas most of type III and IV were due to qualitative mutations in both of the collagen genes. Those with quantitative mutations had milder clinical severity compared to qualitative mutations in terms of dentinogenesis imperfecta (DI), bone deformity and the ability to walk with aid. Furthermore, a few patients (28%, n = 8) had mutations in IFITM5, BMP1, P3H1 and SERPINF1.

CONCLUSION: Majority of our OI patients have mutations in collagen genes, similar to other OI populations worldwide. Genotype-phenotype analysis revealed that qualitative mutations had more severe clinical characteristics compared to quantitative mutations. It is crucial to identify the causative mutations and the clinical severity of OI patients may be predicted based on the types of mutations.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.